151. Metal organic framework-based polymeric hydrogel: A promising drug delivery vehicle for the treatment of breast cancer.
- Author
-
Pandya I, Kumar S, Aswal VK, El Seoud O, Assiri MA, and Malek N
- Subjects
- Humans, MCF-7 Cells, HeLa Cells, Female, Hydrogen-Ion Concentration, Drug Carriers chemistry, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic chemistry, Antimetabolites, Antineoplastic pharmacology, Antineoplastic Agents administration & dosage, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Fluorouracil administration & dosage, Fluorouracil chemistry, Fluorouracil pharmacology, Breast Neoplasms drug therapy, Cell Survival drug effects, Hydrogels chemistry, Drug Liberation, Metal-Organic Frameworks chemistry, Polyvinyl Alcohol chemistry, Drug Delivery Systems methods
- Abstract
The constraints associated with current cancer therapies have inspired scientists to develop advanced, precise, and safe drug delivery methods. These delivery systems boost treatment effectiveness, minimize harm to healthy cells, and combat cancer recurrence. To design advanced drug delivery vehicle with these character, in the present manuscript, we have designed a self-healing and injectable hybrid hydrogel through synergistically interacting metal organic framework, CuBTC with the poly(vinyl alcohol) (PVA). This hybrid hydrogel acts as a localized drug delivery system and was used to encapsulate and release the anticancer drug 5-Fluorouracil selectively at the targeted site in response to the physiological pH. The hydrogel was formed through transforming the gaussian coil like matrix of PVA-CuBTC into a three-dimensional network of hydrogel upon the addition of crosslinker; borax. The biocompatible character of the hydrogel was confirmed through cell viability test. The biocompatible hybrid hydrogel then was used to encapsulate and studied for the pH responsive release behavior of the anti-cancer drug, 5-FU. The in vitro cytotoxicity of the drug-loaded hydrogel was evaluated against MCF-7 and HeLa cells. The study confirms that the hybrid hydrogel is effective for targeted and sustained release of anticancer drugs at cancer sites., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF